Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

AS-i Harju Elekter Group majandustulemused, 1-6/2026

View original at globenewswire.com
“Ärikasum enne kulumit (EBITDA) 2 266 4 658 -51,4% 3 905 8 523 -54,2%”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q2 and H1 2026 results fell significantly short of both revenue and profit targets due to lower-than-expected sales volume and part of revenue shifting to future periods

    60% confidence

  • In Sweden, long-execution-time projects make up a significant share of the order book, with realization extending into 2028

    60% confidence

  • Ongoing preparations and a growing order book create the conditions for servicing larger project volumes and for revenue and profitability growth in future years

    60% confidence

  • 2026 is considered a transition year during which the company prepares for the next high-activity periods, with a stronger order book for H2 than H1

    60% confidence

  • The Estonian local distribution grid operator has reduced its investment volumes, weighing on the local market

    60% confidence

Data points we hold from this source

Harju Elekter Group · net income0.272 USD
Harju Elekter Group · labor costs21.4 USD
Harju Elekter Group · margin12.2 percent
Harju Elekter Group · long term financial investments27.223 USD
Harju Elekter Group · labor cost ratio27.7 percent
Harju Elekter Group · capital expenditure3.9 USD
Harju Elekter Group · admin expenses5.627 USD
Harju Elekter Group · admin expense ratio7.3 percent
Harju Elekter Group · employee wage costs16.7 USD
Harju Elekter Group · ebit margin2.6 percent
Harju Elekter Group · debt35.467 USD
Harju Elekter Group · inventory20.456 USD
Harju Elekter Group · equity95.155 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
AS-i Harju Elekter Group majandustulemused, 1-6/2026 — Source | Via News | Finance Via News